# Yangpu Star Pharmaceutical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/yangpu-star-pharmaceutical-co

- Industry: Healthcare
- Headquarters: Danzhou, China
- Total disclosed funding: $90M
- Latest round: Series C (Jul 23, 2021)
- Investors on record: 5

## About

Based in Danzhou, China and established in 2008, Yangpu Star Pharmaceutical Co.,Ltd is a service provider that focuses on providing pre-clinical and clinical solutions. In 2017, the company changes its name from Yangpu Star Pharmaceutical Co.,Ltd to Hainan Huashi Pharmaceutical Holdings Group. In 2021, the company acquired Naranga (Shanghai) Biomedicine Division. The company has approximately 1,100 employees.

The company engages in providing pre-clinical and clinical solutions. The company also focuses on the research and development of macromolecular biological drugs and special medical foods. The company's special medical food research and development services mainly focus on diseases such as tumor, diabetes, kidney disease and liver disease.

## Funding rounds

- Series C, Jul 23, 2021, $50M — OrbiMed Advisors, Apex Capital, Springs Capital, Zhongyuan Capital, SPDB International Capital
- Series B, Sep 1, 2020, $40M — OrbiMed Advisors, SPDB International Capital
- Series A, Aug 5, 2019 — OrbiMed Advisors

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B, Series C
- SPDB International Capital (https://capitalatlas.ai/funds/spdb-international-capital) — Series B, Series C
- Apex Capital — Series C
- Springs Capital — Series C
- Zhongyuan Capital — Series C